VERTEX PHARMACEUTICALS INC / MA

VERTEX PHARMACEUTICALS INC / MA (VRTX) — Investment Memo

🐂 The Bull Case (Warren’s voice)

• Moat is durable for a decade because of irreplaceable pricing power. Vertex’s CF modulators are the only effective therapy for a lethal genetic disease. Patients have no alternative, insurers must pay, and annual pricing at six figures is backed by life-or-death necessity. This creates a recurring revenue stream with enormous gross margins (>80%) and net margins averaging ~33%.

• Economics are exceptional even for a monopoly. Zero debt, $3.2B free cash flow on $12B revenue, ROE of 21.2% (2025). Capital allocation is disciplined – $4.1B R&D reinvested into pipeline diversification (pain, sickle cell, T1D) and a single sensible acquisition (Alpine Immune Sciences). Share count flat – no dilution, no waste.

• Attractive entry point below $340/share. At a 25% margin of safety on a conservative DCF (assuming slowed growth and terminal rate of 2%), intrinsic value is ~$450. A price of $340 offers a fair risk/reward for the next 5–7 years of CF monopoly cash flows. Below $225 (50% margin), it becomes a no-brainer for a bet on a pipeline lottery ticket.

🐻 The Bear Case (Charlie inverts)

Munger’s rule: “Show me where I’ll die and I won’t go there.”

• Permane impairment #1: A one-time gene-editing cure for CF. Only ~90,000 patients globally. A cure (e.g., CRISPR-based) would eliminate the entire pill franchise overnight. Vertex has no pipeline that competes with a cure – only incremental modulators. This is the most likely structural threat over 10–15 years.

• Permanent impairment #2: Patent cliff + generic entry. Trikafta patents begin expiring in the late 2020s. Next-gen drugs (vanzacaftor) may extend, but generic manufacturers with lower costs will erode pricing power. Without a new blockbuster, revenue drops 80–90% as competition emerges. This is a near-certainty by 2035.

• Permanent impairment #3: Pipeline failure. Vertex is spending $4.1B/year on R&D to diversify into pain, sickle cell, and T1D. None of these are approved. If they fail, the stock is a single-disease company with declining CF revenue. Management’s current credibility rests on pipeline success – a binary bet.

Most likely scenario: Patent cliff + slower-than-expected new drug approvals erode revenue from $12B to $3–4B over the next 12–15 years. The stock would trade at a terminal value of <$200.

💰 Valuation & Margin of Safety

• Intrinsic value estimate: $450/share (based on DCF with 15% FCF growth, 10% discount, 3% terminal). But this terminal growth rate is too optimistic for a shrinking CF monopoly – a more realistic 2% terminal and 12% discount yield ~$370.

• 25% margin of safety entry: $338 (conservative, assumes some pipeline optionality)

• 50% margin of safety entry: $225 (Buffett’s ideal – compensates for binary risk of a cure or patent cliff)

Current price (~$450): Fairly valued with no margin of safety. The market is pricing in high pipeline success odds, which we cannot confirm.

Verdict: PASS

Pass. Vertex’s monopoly on cystic fibrosis is real but finite, and the current price of $450 offers no margin of safety against the binary risk of a cure or patent cliff. We require a 50% discount to intrinsic value to compensate for the terminal risk of single-disease dependence – and that discount does not exist today.